 |
Addressing Cardiology Concerns in Pulmonary Arterial Hypertension (PAH) Care CME Vallerie V. McLaughlin, MD, FACC, FAHA, Chair; Richard N. Channick, MD, FCCP; Richard A. Krasuski, MD; Michael J. Landzberg, MD; Michael A. Mathier, MD, FACC Author Information and Disclosures Release Date: May 28, 2008; Valid for credit through May 28, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "Addressing Cardiology Concerns in Pulmonary Arterial Hypertension (PAH) Care" symposium held in Chicago, Illinois, on March 31, 2008.
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Introductory CommentsVallerie V. McLaughlin, MD, FACC, FAHAAvailable As: Slides/Audio | Slides/Transcript | Audio
- Emerging Role of Advanced Imaging in PAHRichard A. Krasuski, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Oral Therapy for the Mildly/Moderately Symptomatic PAH Patient: Making Sense of the DataRichard N. Channick, MD, FCCPAvailable As: Slides/Audio | Slides/Transcript | Audio
- When and How to Escalate Therapy for PAHMichael A. Mathier, MD, FACCAvailable As: Slides/Audio | Slides/Transcript | Audio
- Assessing and Managing Complex Patient Populations in PAHMichael J. Landzberg, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Discussion: Q & AVallerie V. McLaughlin, MD, FACC, FAHAAvailable As: Slides/Audio | Slides/Transcript | Audio
- Case-Based Clinical Pearls: Case StudyVallerie V. McLaughlin, MD, FACC, FAHAAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medical Education Resources |
|
|
Learning Objectives - Describe the clinical presentation and impact of RV failure in pulmonary hypertension, and evaluate newer RV imaging techniques that might enhance diagnosis and better assess treatment effects.
- Outline state-of-the-art
evidence-based management approaches for patients with early or mild PAH, with a focus on pros and cons of various oral therapies.
- Delineate when and how to escalate therapy in the long-term management of PAH, using a goal-oriented approach to assess patient progress with combination therapy (oral, parenteral, and/or inhaled).
- Identify emerging patient populations with or at risk for PAH, develop appropriate management strategies,
and optimize treatment.
Author Disclosures Richard N. Channick, MD, FCCP
Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: Actelion Pharmaceuticals US, Inc., Gilead Sciences, Inc., Pfizer Inc
Dr Channick has disclosed that his
presentation will reference off-label uses of products.
Richard A. Krasuski, MD
Disclosure: Consultant and/or Speakers' Bureau: Actelion Pharmaceuticals US, Inc., Pfizer Inc
Michael J. Landzberg, MD
Disclosure: Grant/Research Support and/or Consultant: Actelion Pharmaceuticals US, Inc., AGA Medical Corporation, Gilead Sciences, Inc., Nitrox LLC, NMT Medical, Inc., Pfizer
Inc
Michael A. Mathier, MD, FACC
Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: Actelion Pharmaceuticals US, Inc., Encysive Pharmaceuticals, Gilead Sciences, Inc., GlaxoSmithKline, United Therapeutics
Vallerie V. McLaughlin, MD, FACC, FAHA, Chair
Disclosure: Grant/Research Support, Consultant, and/or Speakers' Bureau: Actelion Pharmaceuticals
US, Inc., Encysive Pharmaceuticals, Gilead Sciences, Inc., Pfizer Inc, United Therapeutics
|
 |
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources and Concepts in Medicine. Medical Education Resources is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
